Therapeutic effect of rebamipide on ammonia-induced gastric mucosal hemorrhagic lesion in rats.
Rebamipide, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]-propionic acid, a novel antipeptic ulcer agent, has been reported to prevent various acute experimental gastric mucosal lesions and to accelerate the healing of chronic ulcers. Therapeutic effect of rebamipide was investigated with regard to the inhibitory effect on xanthine oxidase activity and type conversion of the enzyme which play a profound role in oxygen radicals generation system. Intraperitoneal administration of rebamipide at 60 mg/kg body weight reduced the xanthine oxidase activity, lipid peroxide content in ammonia induced hemorrhagic lesion. These results suggest that the therapeutic effect of rebamipide on gastric mucosal lesion may be in part due to the inhibitory activity of xanthine oxidase and type conversion rate of the enzyme.
Huh
K
K
Department of Pharmacology, College of Pharmacy, Yeungnam University, Gyongsan, Korea.
Kwon
T H
TH
Kim
S K
SK
Kim
J S
JS
Shin
U S
US
D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000641:Ammonia; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D015227:Lipid Peroxidation / Q000187:drug effects; D008054:Lipid Peroxides / Q000378:metabolism; D008297:Male; D015363:Quinolones / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014968:Xanthine Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000378:metabolism
D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D008054:Lipid Peroxides; D015363:Quinolones; D000641:Ammonia; D014968:Xanthine Dehydrogenase; D014969:Xanthine Oxidase; C052785:rebamipide; D000409:Alanine